BioPharmSignal logoBioPharmSignal

Biotech News

Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients

Tonix Pharmaceuticals (TNXP)Tonix PharmaceuticalsCommercial

TNXP (TNXP) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is tnxp.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

TNXPTonix Pharmaceuticals2026-06-08 11:00 EST

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives

TNXPTonix Pharmaceuticals2026-07-13 11:00 EST

Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®

ECORelectroCore2026-04-23 12:00 EST

electroCore Product Line Featured in Documentary Underscoring the Expanding Clinical and Commercial Role of Vagus Nerve Stimulation

NBIXNeurocrine Biosciences2026-05-18 12:46 EST

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

ECORelectroCore2026-07-16 12:00 EST

New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation

TEVATeva Pharmaceutical Industries2026-06-04 12:30 EST

Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®

XENEXenon2026-05-01 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ABOSAcumen Pharmaceuticals2026-06-16 11:30 EST

Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease

View all latest news

Tonix Pharmaceuticals

Tonix Pharmaceuticals is a neuroscience and infectious-disease company with a wide-ranging pipeline and a long-running development story. Its business has included central nervous system, pain, and vaccine-related programs.

Recent company news

TNXPTonix Pharmaceuticals2026-07-27 11:00 EST

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

TNXPTonix Pharmaceuticals2026-07-15 13:05 EST

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models

TNXPTonix Pharmaceuticals2026-07-13 11:00 EST

Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®

TNXPTonix Pharmaceuticals2026-06-29 11:25 EST

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)

TNXPTonix Pharmaceuticals2026-06-11 11:00 EST

Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026

Stock data

Close
9.94 USD
Market cap
186.83M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States